🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
155.39
-1.20 (-0.77%)
Nov 20, 2026, 10:11 AM EST - Market open

Neurocrine Biosciences Stock Forecast

Stock Price Forecast

According to 28 analysts polled by S&P Global, Neurocrine Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $208.54. The average 1-year stock price forecast is 34.20% higher than the current stock price, while the lowest is $150 (-3.47%) and the highest is $253 (+62.82%).

Price Target: $208.54 (+34.20%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$150$208.54$215$253
Change-3.47%+34.20%+38.36%+62.82%

Analyst Ratings

The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy212020212120
Buy444444
Hold444444
Sell000000
Strong Sell000000
Total292828292928

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Morgan Stanley
Morgan Stanley
Hold
Maintains
$185 → $191
HoldMaintains$185 → $191+22.92%Nov 13, 2026
Bernstein
Bernstein
Buy
Maintains
$218
BuyMaintains$218+40.29%Nov 4, 2026
Guggenheim
Guggenheim
Buy
Reiterates
$207 → $224
BuyReiterates$207 → $224+44.15%Nov 4, 2026
Bank of America Securities
Bank of America Securities
Buy
Reiterates
n/a
BuyReiteratesn/an/aNov 3, 2026
BMO Capital
BMO Capital
Hold
Maintains
$150
HoldMaintains$150-3.47%Nov 3, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
3.99B
from 2.86B
Increased by 39.62%
Revenue Next Year
4.58B
from 3.99B
Increased by 14.75%
EPS This Year
10.59
from 6.39
Increased by 65.72%
EPS Next Year
12.30
from 10.59
Increased by 16.14%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
1.13B1.49B1.89B2.36B2.86B3.99B
Revenue Growth
8.38%31.34%26.76%24.81%21.45%39.62%
Operating Income
207.80M249.00M394.80M597.00M636.50M966.99M
Net Income
89.60M154.50M249.70M341.30M478.60M782.78M
EPS
----6.3910.59
EPS Growth
----0.95%65.72%
Forward PE
24.5522.5321.3418.1515.8714.67
Free Cash Flow
----748.70M936.48M
No. Analysts
-----23
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High4.2B
Avg4.0B
Low4.0B

Revenue Growth

Revenue Growth202620272028
High
46.0%
Avg
39.6%
Low
38.1%

EPS Forecast

EPS202620272028
High12.39
Avg10.59
Low9.35

EPS Growth

EPS Growth202620272028
High
93.9%
Avg
65.7%
Low
46.3%